Please read and agree to the terms and conditions of this site.
@xconomy.com 3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com 4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com 4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com 5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com 5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines